Fludarabine

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsed or Refractory Large B-cell Lymphoma

Drug Information

Target Indication

Relapsed or Refractory Large B-cell Lymphoma

Clinical Trial

Last updated: 1/29/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

GILD

Gilead Sciences, Inc.

Related Pipeline

Pre-Exposure Prophylaxis of HIV Infection

HIV Infections

HIV-1 Infection

Cystic Fibrosis

Locally Advanced or Metastatic Unresectable Urothelial Cancer